Onder Ali Mirza, Kato Tomoaki, Simon Nancy, Rivera-Hernandez Maria, Chandar Jayanthi, Montane Brenda, Francoeur Denise, Salvaggi Genaro, Tzakis Andreas G, Zilleruelo Gaston
Division of Pediatric Nephrology, Department of Pediatrics, University of Miami/Holtz Children's Hospital, Miami, FL 33101, USA.
Pediatr Transplant. 2007 Feb;11(1):87-93. doi: 10.1111/j.1399-3046.2006.00634.x.
Catheter-related bacteremia (CRB), along with liver failure is the leading cause of mortality and morbidity in parenteral nutrition dependent children. Immunosuppressant therapy following transplantation increases the risk of CRB. Previous reports in pediatric cancer patients have described the use of antibiotic lock solutions (ABL) for prophylaxis of CRB. In our institution, we evaluated five children (ages between one and four yr old), three with intestinal transplantation and two with short gut syndrome, who were high risk for recurrent CRB defined by their incidence of bacteremias in the observation period (>2 CRB/six months or life-threatening CRB). These children received the prophylactic ABL protocol with tobramycin-tissue plasminogen activator, four h per day, on alternating ports for six to eight months. Each patient was his/her own historical control. We observed decreased incidence of CRB's (p < 0.05), days of hospitalization due to CRB's (p < 0.0001), the days of intensive care admissions due to CRB (p < 0.0001), as well as the total days of systemic antibiotic exposure (p < 0.001). Catheter survival during the ABL era was longer but not reaching statistical significance. There was no advantage in removing and later replacing the catheter to wire-guided exchange while on systemic antibiotics. One patient presented with break-through bacteremia, septic shock and died. None of the catheters were lost to occlusion/malfunction. ABL did not induce an increased resistance to tobramycin. These preliminary findings suggest that ABL can be used safely and effectively in parenteral nutrition dependent children with long-term central venous catheters.
导管相关菌血症(CRB)与肝衰竭一样,是肠外营养依赖儿童死亡和发病的主要原因。移植后的免疫抑制治疗会增加CRB的风险。先前关于儿科癌症患者的报告描述了使用抗生素封管液(ABL)预防CRB。在我们机构,我们评估了五名儿童(年龄在1至4岁之间),其中三名患有肠道移植,两名患有短肠综合征,根据他们在观察期内的菌血症发生率(>2次CRB/六个月或危及生命的CRB),他们属于复发性CRB的高危人群。这些儿童接受了含妥布霉素-组织纤溶酶原激活剂的预防性ABL方案,每天4小时,在交替端口进行,持续6至8个月。每名患者均以自身作为历史对照。我们观察到CRB的发生率降低(p<0.05),因CRB导致的住院天数减少(p<0.0001),因CRB导致的重症监护入院天数减少(p<0.0001),以及全身抗生素暴露的总天数减少(p<0.001)。ABL时代的导管存活时间更长,但未达到统计学意义。在使用全身抗生素时,拔除导管并随后通过导丝引导更换导管并无优势。一名患者出现突破性菌血症、感染性休克并死亡。没有导管因堵塞/故障而丢失。ABL并未导致对妥布霉素的耐药性增加。这些初步研究结果表明,ABL可安全有效地用于长期中心静脉置管的肠外营养依赖儿童。